Payment overview · 2025
General Payments
$277.33
15 reported records · 8 companies
Healthcare provider profile · identity verified
Rowena Santos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1700942224
Verified facts
What the public records show
CMS Open Payments records show Rowena Santos, MD received $277.33 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.26 | 36.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.72 | 18.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.27 | 14.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.47 | 9.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.76 | 5.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.20 | 5.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.10 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.55 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.33 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.68 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $50.72 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $50.72 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.27 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 55 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
55 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 574 | 154 |
| Lisinopril | Lisinopril | 489 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 98 |
| Losartan Potassium | Losartan Potassium | 367 | 92 |
| Omeprazole | Omeprazole | 282 | 79 |
| Alprazolam | Alprazolam | 274 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 242 | 70 |
| Tramadol Hcl | Tramadol Hcl | 236 | 69 |
| Gabapentin | Gabapentin | 204 | 68 |
| Trazodone Hcl | Trazodone Hcl | 204 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 60 |
| Sertraline Hcl | Sertraline Hcl | 171 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 38 |
| Meloxicam | Meloxicam | 169 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 47 |
| Methylprednisolone | Methylprednisolone | 150 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 51 |
| Metformin Hcl | Metformin Hcl | 144 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 46 |
| Simvastatin | Simvastatin | 129 | 34 |
| Alendronate Sodium | Alendronate Sodium | 119 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 34 |
| Furosemide | Furosemide | 110 | 37 |
| Ozempic | Semaglutide | 109 | 20 |
| Glipizide | Glipizide | 104 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 30 |
| Cephalexin | Cephalexin | 89 | 60 |
| Eliquis | Apixaban | 84 | 15 |
| Lovastatin | Lovastatin | 84 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 17 |
| Buspirone Hcl | Buspirone Hcl | 76 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 27 |
| Allopurinol | Allopurinol | 70 | 18 |
| Azithromycin | Azithromycin | 70 | 57 |
| Potassium Chloride | Potassium Chloride | 68 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 21 |
| Montelukast Sodium | Montelukast Sodium | 64 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 15 |
| Carvedilol | Carvedilol | 57 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 55 | 55 |
| Bupropion Xl | Bupropion Hcl | 55 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Amoxicillin | Amoxicillin | 51 | 46 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 15 |
| Atenolol | Atenolol | 44 | 13 |
| Pregabalin | Pregabalin | 44 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 38 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 16 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Prednisone | Prednisone | 31 | 20 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Benzonatate | Benzonatate | 30 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 14 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Diazepam | Diazepam | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.33 · 15 records | ABBVIE INC. | AREXVY, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, KISUNLA, NURTEC ODT, PROLIA, QULIPTA, SHINGRIX, UBRELVY, VRAYLAR, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error